Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

An infiltration of >30 eosinophils per high-power field in at least five high-power fields, exhibiting signs of eosinophilic degranulation and extending to the muscularis mucosa or submucosa are ...

CITRYLL DEMONSTRATES A BROADER THERAPEUTIC POTENTIAL FOR CIT-013 IN THE TREATMENT OF INFLAMMATORY DISORDERS Breakthrough study published in ...

Acute respiratory infections (ARIs) are a common cause of illness in children younger than 16 years and adults older than 65 ...

Tezepelumab's greatest potential lies in non-eosinophil severe asthma however – which isn't addressed by the current biologics. ICER notes that patients with non-eosinophilic asthma treated with ...

In the phase 3 ENHANCE trials, Ohtuvayre was shown to reduce exacerbation rate and risk over 24 weeks in COPD patients, regardless of blood eosinophil levels, compared to placebo, and also improve ...